Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 16, Leerink Partners analyst Joseph Schwartz reiterated the firm’s bullish stance on Travere Therapeutics, Inc. (NASDAQ:TVTX), assigning it a Buy rating and a $42 price target. The analyst supported the positive rating with Travere Therapeutics, Inc.’s (NASDAQ:TVTX) positive trajectory, supported by its product Filspari, which attained complete approval for the treatment of IgA nephropathy (IgAN) in 2023.

Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently

A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule.

When considered in conjunction with the updated treatment guidelines, this approval has resulted in a notable growth in Filspari’s market presence. Although competition is anticipated to rise in the IgAN market, the firm anticipates Filspari to hold a competitive market edge due to its full approval status, as other treatments only have accelerated approval.

Schwartz also reasoned that Travere Therapeutics, Inc. (NASDAQ:TVTX) is looking into expansion opportunities in focal segmental glomerulosclerosis (FSGS), and a supplemental New Drug Application is under review by the FDA. While such processes have inherent regulatory risks, the analyst expressed optimism about Travere Therapeutics, Inc.’s (NASDAQ:TVTX) prospects because of its strategic positioning and management’s confidence.

Guggenheim analyst Vamil Divan also reiterated a Buy rating on Travere Therapeutics, Inc.’s (NASDAQ:TVTX) on July 2 with a price target of $47.00.

Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company that identifies, develops, and delivers therapies for rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), reduces proteinuria in individuals with primary IgAN at risk of rapid disease progression. The company’s commercial products, Thiola and Thiola EC, treat cystinuria, a rare genetic cystine transport disorder.

While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.